Catheter Precision reports Q3 revenue $96,000

David Jenkins, CEO of Catheter Precision (VTAK), commented, “We could not be more excited to see both the clinical data and the commercial execution coming together at this point. The number of studies and publications that should result from them over the coming months should provide evidence to the medical community of the effectiveness and necessity of both our LockeT and VIVO product lines. The new sales and clinical team have now been on board for their first full quarter, and we are seeing the results of our investment coming through on the pipeline. We have invested significantly in our business, and the majority of our net loss for the third quarter relates to expenses for commercial activities. We are now gaining confidence in our commercial execution, including what we hope will be positive sales revenue results in the coming quarters. We now have in place a strong clinical trial program for both products as well as a publication plan to put forth the trial results. This too has required and will continue to require additional investment, but we are proud to have accomplished this on a relatively tight budget. Other companies are now starting trials for ablation catheters, specifically for VT. This confirms our outlook for VIVO and its need in these types of procedures. We continue to believe that the ventricular market, although small today, could one day be as large as the atrial fib market. New tools, such as VIVO, can make that happen. Overall, the electrophysiology market is strong, and we intend to be a meaningful player, providing unique and clinically relevant products to this market.”